Immunotherapy in SMARCB1 (INI-1)-deficient sinonasal carcinoma: Two case reports

Figure 1 Preoperative T1 post contrast magnetic resonance images of Case 1 and 2. A and D: Axial section; B and E: Coronal section; C and F: Sagittal section.

Figure 2 Histopathological and immunohistochemical features of Case 1. A: Tumor cells grew as nested (hematoxylin and eosin staining, ×200); B and C: The tumor cells were positive for creatine-kinase (×100) and negative for S-100 (×100); D: The Ki-67 proliferative index was approximately 70% (×100); E: INI-1 expression was present in the nuclei of surrounding non-neoplastic cells but completely absent in the tumor cells (×100).

Figure 3 Histopathological and immunohistochemical features of Case 2. A and B: Tumor cells had no clear differentiation, glandular morphology and mucoid interstitial substance could be observed in some areas. (Hematoxylin and eosin staining, ×200); C-J: The tumor cells were diffuse positivity for CK(x100), CK8/18 (×100), partial positivity for P40 (×100), P63 (×100), S-100 (×100), Syn (×100), and negativity for CK7 (×100), LCA (×100); K: Tumors had a PD-L1 combined positive score of one (×100); L: The Ki-67 proliferative index was approximately 70% (×100).

Figure 4 Timeline of Case 1’s clinical management and outcome. MRI: Magnetic resonance imaging; SDSC: SMARCB1-deficient sinonasal carcinomas.

Figure 5 Timeline of Case 2’s clinical management and outcome. SDSC: SMARCB1-deficient sinonasal carcinomas.

Figure 6 SMARCB1 is a tumor suppressor gene located at chromosome 22q11. 2. The protein encoded by this gene is a core subunit of the switch/sucrose nonfermenting complex, which can be ubiquitously expressed in the nucleus of all normal cells and can participate in regulating transcription and many other functions of cells.

Figure 7 Selected publications further studied SMARCB1-deficient sinonasal carcinoma. SDSC: SMARCB1-deficient sinonasal carcinomas.